Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Inspections topic
No spam. Unsubscribe anytime.
FDA outlines what inspectors evaluate in pre‑approval and pre‑license biologics inspections
Summary
FDA DMPQ described inspection timing, logistics, and the seven systems inspectors examine (quality, facility/equipment/HVAC, production, materials, labeling/packaging, laboratory controls, donor eligibility) and highlighted common Form 483 themes including weak quality oversight, poor environmental monitoring and inadequate OOS investigations.
Dr. Holly Brevik reviewed FDA pre‑license (PLI) and pre‑approval (PI) inspection processes for biologics. Under the Public Health Service Act and FD&C Act, a biologics license cannot be issued unless both product and establishment meet standards; inspections are therefore a core element of application review.
Brevik explained the distinction between SBER product‑specific PLI/PIs (typically announced, focused on the BLA or supplement) and Office of Investigations surveillance inspections (typically unannounced, facility‑wide). Inspectors request an up‑to‑date production schedule to schedule inspections, use a SharePoint guest collaboration site for document exchange and hold a pre‑inspection teleconference to confirm logistics. Inspections include opening presentations, facility walkthroughs, daily records review, operator interviews and observation of live operations; any deficiencies are summarized in a Form 483 at closeout.
Inspectors focus on seven major systems: quality system (SOPs, deviations, CAPA and quality unit independence), facility/equipment (design, segregation, HVAC qualification and maintenance), production system (batch records, aseptic practice and APS), materials system (incoming testing, quarantine/release), labeling and packaging (label reconciliation and line clearance), laboratory controls (method validation, OOS handling, data integrity), and donor eligibility when applicable.
Common Form 483 observations Brevik cited included inadequate quality oversight (poor deviation investigations and failure to demonstrate CAPA effectiveness), deteriorating cleanroom surfaces, incomplete EM programs (poor sampling location choices), OOS handling deficiencies and weak shipping validations. She advised firms to be inspection‑ready at submission because unresolved inspectional issues can delay or prevent approval, and to provide comprehensive corrective and preventive action plans with realistic implementation timelines.
Brevik also summarized response logistics: facilities should reply to Form 483 observations within 15 business days and provide comprehensive CAPA plans; FDA may require evidence of implementation before licensing decisions are finalized.
